Safety and tolerability of immune globulin intravenous (human), 10% solution in Japanese subjects with mild to moderate Alzheimer's disease

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Psychogeriatrics

• Publication date

  2014-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/psyg.12055PMID 25186799
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial.

  2013cited by this paper
• 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

  2009cited by this paper
• O2–05–05: IVIg contains antibodies against oligomers and fibrils of beta amyloid

  2007cited by this paper
• Intravenous immunoglobulin enhances the clearance of fibrillar amyloid‐β peptide

  2006cited by this paper
• Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide.

  2006cited by this paper
• Diagnostic and Therapeutic Potential of Amyloid-Reactive IgG Antibodies Contained in Human Sera1

  2006cited by this paper
• Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

  2005cited by this paper
• Alzheimer Disease: Mechanistic Understanding Predicts Novel Therapies

  2004cited by this paper
• Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer’s disease

  2004cited by this paper
• Pain: Moving from Symptom Control toward Mechanism-Specific Pharmacologic Management

  2004cited by this paper
• Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

  2003cited by this paper
• Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

  2003cited by this paper
• Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis

  2003cited by this paper
• Slow Cognitive Decline in Alzheimer’s Disease

  2003cited by this paper
• Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals.

  2002cited by this paper
• Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy

  2002cited by this paper
• Progressive loss of cardiac sympathetic innervation in Parkinson's disease

  2002cited by this paper
• Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease

  2001cited by this paper
• Reduced levels of amyloid β-peptide antibody in Alzheimer disease

  2001cited by this paper
• A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

  2000cited by this paper
• Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

  2000cited by this paper
• Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

  2000cited by this paper
• Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

  1999cited by this paper
• Adverse Effects of Intravenous Immunoglobulin Therapy

  1999cited by this paper
• Neuroautoimmunity: pathogenic implications for Alzheimer's disease.

  1997cited by this paper
• APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease.

  1996cited by this paper
• Adverse effects of intravenous immunoglobulin therapy.

  1996cited by this paper
• Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies

  1993cited by this paper

• Can IVIG Intervene in AD? Insights from Animal Experiments and Clinical Trials—A Systematic Review and Synthesis Without Meta-Analysis

  2026cites this paper
• Antibody Assay and Anti-Inflammatory Function Evaluation of Therapeutic Potential of Different Intravenous Immunoglobulins for Alzheimer’s Disease

  2023cites this paper
• Neuroprotective Effects of IVIG against Alzheimer’s Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice

  2023cites this paper
• Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders

  2021cites this paper
• Efficacy and safety of blood derivatives therapy in Alzheimer’s disease: a systematic review and meta-analysis

  2021cites this paper
• Intravenous immunoglobulins for Alzheimer’s disease and mild cognitive impairment due to Alzheimer’s disease: A systematic review with meta-analysis

  2019cites this paper
• Intravenous Immunoglobulin for Patients With Alzheimer’s Disease: A Systematic Review and Meta-Analysis

  2019cites this paper
• Efficacy, Acceptability, and Safety of Intravenous Immunoglobulin Administration for Mild-To-Moderate Alzheimer’s Disease: A Systematic Review and Meta-Analysis

  2018cites this paper
• Neuroactive compounds obtained from arthropod venoms as new therapeutic platforms for the treatment of neurological disorders

  2015cites this paper